

=> FIL STNGUIDE  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
130.45	217.56

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.12	-3.12

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 11:26:44 ON 13 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Mar 9, 2007 (20070309/UP).

=> d his full

(FILE 'HOME' ENTERED AT 11:02:36 ON 13 MAR 2007)

FILE 'REGISTRY' ENTERED AT 11:02:49 ON 13 MAR 2007

L1 1 SEA TAMOXIFEN/CN  
D L1

FILE 'WPIDS' ENTERED AT 11:10:27 ON 13 MAR 2007

L2 4 SEA TAMOXIFEN (P) HYDROALCOHOLIC  
D L2 1-4 BIB,KWIC

L3 1 SEA HYDROALCOHOLIC AND DANAZOL  
D L3 BIB,KWIC

L4 282 SEA HYDROALCOHOLIC/AB

L5 0 SEA L4 AND DANAZOL

FILE 'REGISTRY' ENTERED AT 11:15:34 ON 13 MAR 2007

L6 1 SEA DANAZOL/CN  
D L6

FILE 'WPIDS' ENTERED AT 11:15:51 ON 13 MAR 2007

L7 282 SEA HYDROALCOHOLIC/AB

L8 0 SEA L7 AND L6

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB,  
DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIODASE,  
IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI,  
MEDLINE, NAPRALERT, NLDB, NUTRACEUT, PASCAL, ...' ENTERED AT 11:16:17 ON  
13 MAR 2007

L9 6618 SEA DANAZOL/AB

L10 69 SEA L9 AND (TOPICAL OR EXTERNAL)/AB

L11 49 SEA L10 AND PD<2004

L12 22 DUP REM L11 (27 DUPLICATES REMOVED)

L13 1 SEA L12 AND (BREAST)

D L13 BIB,KWIC

D L12 1-22 BIB,AB

FILE 'STNGUIDE' ENTERED AT 11:26:44 ON 13 MAR 2007

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2007 HIGHEST RN 926069-79-6  
DICTIONARY FILE UPDATES: 12 MAR 2007 HIGHEST RN 926069-79-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE WPIDS

FILE LAST UPDATED: 5 MAR 2007 <20070305/UP>

MOST RECENT THOMSON SCIENTIFIC UPDATE: 200716 <200716/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> New display format FRAGHITSTR available <<<

SEE ONLINE NEWS and

[http://www.stn-international.de/archive/stn\\_online\\_news/fraghitstr\\_ex.pdf](http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.pdf)

>>> IPC Reform reclassification data for the backfile is being  
loaded into the database during of January 2007.

There will not be any update date (UP) written for the reclassified  
documents, but they can be identified by 20060101/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:

[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf)

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

[http://www.stn-international.de/stndatabases/details/ipc\\_reform.html](http://www.stn-international.de/stndatabases/details/ipc_reform.html) and

<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf>

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX

PLEASE SEE

[http://www.stn-international.de/stndatabases/details/dwpi\\_r.html](http://www.stn-international.de/stndatabases/details/dwpi_r.html) <<<

FILE ADISCTI

FILE COVERS 1998 TO 9 Mar 2007 (20070309/ED)

FILE LAST UPDATED: 9 MAR 2007 (20070309/ED)

Reloaded 27 Aug. 2006; enter HELP RLOAD for details.

FILE ADISINSIGHT

FILE COVERS 1998 TO 8 Mar 2007 (20070308/ED)

FILE LAST UPDATED: 8 MAR 2007 (20070308/ED)

FILE ADISNEWS

FILE COVERS 1983 TO 13 Mar 2007 (20070313/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 7 March 2007 (20070307/ED)

FILE BIOTECHNO

FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>

FILE COVERS 1980 TO 2003.

>>> BIOTECHNO IS NO LONGER BEING UPDATED AS OF 2004 <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN /CT AND BASIC INDEX <<<

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Mar 2007 VOL 146 ISS 12

FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE DDFB

>>> FILE COVERS 1964 TO 1982 - CLOSED FILE <<<

FILE DGENE

FILE LAST UPDATED: 9 MAR 2007 <20070309/UP>

DGENE CURRENTLY CONTAINS 8,504,840 BIOSEQUENCES

>>> ONLINE THESAURUS AVAILABLE IN /PACO <<<

>>> DOWNLOAD THE DGENE WORKSHOP MANUAL:

[http://www.stn-international.de/training\\_center/bioseq/dgene\\_wm.pdf](http://www.stn-international.de/training_center/bioseq/dgene_wm.pdf)

>>> DOWNLOAD COMPLETE DGENE HELP AS PDF:

[http://www.stn-international.de/training\\_center/bioseq/dgene\\_help.pdf](http://www.stn-international.de/training_center/bioseq/dgene_help.pdf) <<

>>> DOWNLOAD DGENE BLAST/GETSIM FREQUENTLY ASKED QUESTIONS:

<http://www.stn-international.de/service/faq/dgenefaq.pdf> <<<

FILE DISSABS

FILE COVERS 1861 TO 26 FEB 2007 (20070226/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

FILE DRUGB

>>> FILE COVERS 1964 TO 1982 - CLOSED FILE <<<

FILE DRUGMONOG2

FILE IS CURRENT THROUGH 20 Feb 2007 (20070220/ED)

```
#####
#
#                               !!! ATTENTION !!!
#
# Welcome to DRUGMONOG2. This file is available to all users. #
# To access drug pricing information, use DRUGMONOG, accessible #
# only to pharmaceutical organizations for reasons of #
# confidentiality. #
#
# If you already have subscription status on any of the IMSworld#
# files on STN and belong to a pharmaceutical organization, you #
# should automatically have access to DRUGMONOG. If you belong #
# to a pharmaceutical organization and would like to use #
# DRUGMONOG, please contact your STN Help Desk. If you do not #
# need pricing information, use DRUGMONOG2. #
#
# See HELP SUBSCRIPTION for more information. #
#####
```

FILE DRUGU

FILE LAST UPDATED: 9 MAR 2007 <20070309/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<

>>> THESAURUS AVAILABLE IN /CT <<<

FILE EMBAL

FILE COVERS CURRENT RECORDS AND IS UPDATED DAILY

FILE LAST UPDATED: 12 MAR 2007 (20070312/ED)

FILE EMBASE

FILE COVERS 1974 TO 12 Mar 2007 (20070312/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE ESBIODBASE

FILE LAST UPDATED: 13 MAR 2007

<20070313/UP>

FILE COVERS 1994 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN  
/CC, /ORGN, AND /ST <<<

FILE IFIPAT

FILE COVERS 1950 TO PATENT PUBLICATION DATE: 8 Mar 2007 (20070308/PD)  
FILE LAST UPDATED: 12 Mar 2007 (20070312/ED)  
HIGHEST GRANTED PATENT NUMBER: US7188369  
HIGHEST APPLICATION PUBLICATION NUMBER: US2007056070  
UNITERM INDEXING IS AVAILABLE IN THE IFIUDB FILE  
UNITERM INDEXING LAST UPDATED: 15 Feb 2007 (20070215/UP)  
INDEXING CURRENT THROUGH PAT PUB DATE: 28 Nov 2006 (20061128/PD)

IFIPAT reloaded on 2/25/07. Enter HELP RLOAD for details.

FILE IMSDRUGNEWS

FILE COVERS 1995 TO 9 Mar 2007 (20070309/ED)

```
#####  
#                                                                    #  
#                               !!! ATTENTION !!!                      #  
#                                                                    #  
# Welcome to IMSDRUGNEWS. This is the Drug News file from          #  
# IMSworld Publications.                                           #  
#                                                                    #  
# For detailed information regarding the printed version           #  
# of this file, please contact IMS HEALTH Customer Services       #  
# directly by phone at +44(0)20-7393-5888, or email                #  
# globaldirect@uk.imshealth.com.                                   #  
#                                                                    #  
# See HELP SUBSCRIPTION for more information.                      #  
#####
```

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

The file name was changed from DRUGNL to IMSDRUGNEWS on 7 Dec. 2003.  
The file name DRUGNL is now an alias for IMSDRUGNEWS.

FILE IMSPRODUCT

FILE COVERS 1982 TO 1 Mar 2007 (20070301/ED)

```
#####  
#                                                                    #  
#                               !!! ATTENTION !!!                      #  
#                                                                    #  
# Welcome to IMSPRODUCT. A special subscriber rate is             #  
# available to purchasers of the IMSworld publication,            #  
# Drug Launches.                                                  #  
#                                                                    #  
# For detailed information regarding eligibility and               #  
# authorization for this subscriber discount, please contact       #  
# IMS HEALTH Customer Services directly by phone                  #  
# at +44(0)20-7393-5888, or email globaldirect@uk.imshealth.com  #  
# See HELP SUBSCRIPTION for more information.                     #  
#                                                                    #  
#####
```

The file name was changed from DRUGLAUNCH to IMSPRODUCT on 7 Dec. 2003.  
The file name DRUGLAUNCH is now an alias for IMSPRODUCT.

FILE IPA

FILE COVERS 1970 TO 1 MAR 2007 (20070301/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE JICST-EPLUS  
FILE COVERS 1985 TO 5 MAR 2007 (20070305/ED)

The database producer has informed us that as of March 31, 2007, they will no longer provide updates for the JICST-EPLUS file. Therefore, effective March 31, 2007, JICST-EPLUS will be removed from STN.

FILE KOSMET  
FILE LAST UPDATED: 5 MAR 2007 <20070305/UP>  
FILE COVERS 1968 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE  
IN THE BASIC INDEX (/BI) FIELD <<<

FILE LIFESCI  
FILE COVERS 1978 TO 18 Jan 2007 (20070118/ED)

FILE MEDLINE  
FILE LAST UPDATED: 10 Mar 2007 (20070310/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE NAPRALERT

FILE COVERS 1650 TO 8 AUG 2005 (20050808/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The NAPRALERT File is no longer being updated. \*\*\*\*\*

FILE NLDB  
FILE COVERS 1988 TO 13 Mar 2007 (20070313/ED)

FILE NUTRACEUT  
FILE LAST UPDATED: 27 FEB 2007 <20070227/UP>  
FILE COVERS MAY 1996 TO DATE

FILE PASCAL  
FILE LAST UPDATED: 12 MAR 2007 <20070312/UP>  
FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE  
IN THE BASIC INDEX (/BI) FIELD <<<

FILE PCTGEN  
FILE LAST UPDATED: 8 MAR 2007 <20070308/UP>  
MOST RECENT PCT PUB DATE: 8 MAR 2007 <20070308/PD>

PCTGEN CURRENTLY CONTAINS 4,770,199 BIOSEQUENCES

>>> DOWNLOAD THE PCTGEN WORKSHOP MANUAL:  
[http://www.stn-international.de/training\\_center/bioseq/pctgen\\_wm.pdf](http://www.stn-international.de/training_center/bioseq/pctgen_wm.pdf)

>>> DOWNLOAD COMPLETE PCTGEN HELP AS PDF:  
[http://www.stn-international.de/training\\_center/bioseq/pctgen\\_help.pdf](http://www.stn-international.de/training_center/bioseq/pctgen_help.pdf)

>>> DOWNLOAD RUN BLAST/GETSIM FREQUENTLY ASKED QUESTIONS:  
<http://www.stn-international.de/service/faq/dgenefaq.pdf> <<<

FILE PHARMAML  
FILE LAST UPDATED: 12 MAR 2007 <20070312/UP>  
FILE COVERS 1992 TO DATE

<<< DISPLAY PRICES FOR THE MOST CURRENT 4-WEEKS INFORMATION  
DIFFER FROM THE PREVIOUS ONES ==> see HELP COST >>>

FILE PHIC  
FILE COVERS CURRENT RECORDS AND IS UPDATED DAILY  
FILE LAST UPDATED: 12 MAR 2007 (20070312/ED)

FILE PHIN  
FILE COVERS 1980 TO 9 MAR 2007 (20070309/ED)

FILE SCISEARCH

FILE COVERS 1974 TO 8 Mar 2007 (20070308/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details..

FILE TOXCENTER

FILE COVERS 1907 TO 6 Mar 2007 (20070306/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2007 MeSH terms.and  
See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the  
MeSH 2007 vocabulary.

FILE USPATFULL  
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 13 Mar 2007 (20070313/PD)  
FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)  
HIGHEST GRANTED PATENT NUMBER: US7191469  
HIGHEST APPLICATION PUBLICATION NUMBER: US2007056070  
CA INDEXING IS CURRENT THROUGH 13 Mar 2007 (20070313/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 13 Mar 2007 (20070313/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 8 Mar 2007 (20070308/PD)  
FILE LAST UPDATED: 8 Mar 2007 (20070308/ED)  
HIGHEST GRANTED PATENT NUMBER: US2005244797  
HIGHEST APPLICATION PUBLICATION NUMBER: US2007056067  
CA INDEXING IS CURRENT THROUGH 6 Mar 2007 (20070306/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 8 Mar 2007 (20070308/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 9, 2007 (20070309/UP).

=>



L17 ANSWER 1 OF 9 USPATFULL on STN  
 AN 2006:282074 USPATFULL  
 TI Novel compounds with high therapeutic index  
 IN Chandran, V. Ravi, Allen, TX, UNITED STATES  
 PI US 2006241017 A1 20061026  
 AI US 2006-343557 A1 20060130 (11)  
 RLI Continuation-in-part of Ser. No. WO 2004-US24901, filed on 29 Jul 2004,  
 PENDING  
 PRAI US 2003-491331P 20030729 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300,  
 GARDEN CITY, NY, 11530, US  
 CLMN Number of Claims: 39  
 ECL Exemplary Claim: 1  
 DRWN 10 Drawing Page(s)  
 LN.CNT 8798  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 DETD . . . p, q inflammation  
 IM Injection 2-200 mg/ml 5-150 mg/ml 10-100 mg/ml  
 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr,  
 especially from  
**Topical Cream** 0.001-5% 0.01-2.5% 0.1-2%  
 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp,  
 infections, tissue  
 Ort, Cav, Asn, Gln, Can, . . . mg 10-350 mg 25-250 mg  
 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr,  
 l, n, o, p, q fibrostatic **breast**  
 Oral Liquid 2-500 mg/ 10-350 mg/ 25-250 mg/  
 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp,  
 disease  
 5 ml 5. . .  
 DETD . . . treatment of psoriasis  
 Preferred Forms  
 Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly  
 k, l, o, p and acne especially  
**Topical Gel** 0.01-0.3% 0.02-0.25%  
 0.025-0.125% His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr,  
 those caused by  
 Phe, Trp, Hyp, Hsr, . . . Val, Pro, His, Tyr,  
 acting on cell  
 day day day  
 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp,  
 membrane changing  
**Topical Cream** 0.01-10% 0.1-5% 0.5-2%  
 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and  
 its permeability  
 Tau, DjK, GABA, Cys, Ser, . . . j, l, treating cancer,  
 Preferred Forms  
 Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Val & Sar  
 o, p especially **breast**  
 IM Injection 2-1250 mg/ 10-1000 mg/ 20-500 mg/  
 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr,  
 cancer  
 5 ml 5. . .  
 IT 51-35-4, Hydroxyproline 52-90-4, Cysteine, reactions 56-12-2, GABA,  
 reactions 56-40-6, Glycine, reactions 56-41-7, L-Alanine, reactions  
 56-45-1, L-Serine, reactions 56-84-8, L-Aspartic acid, reactions  
 56-85-9, L-Glutamine, reactions 56-86-0, L-Glutamic acid, reactions  
 56-87-1, L-Lysine, reactions 56-89-3, Cystine, reactions 60-18-4,  
 L-Tyrosine, reactions 61-90-5, L-Leucine, reactions 63-68-3,  
 L-Methionine, reactions 63-91-2, L-Phenylalanine, reactions 70-26-8,

Ornithine 70-47-3, L-Asparagine, reactions 71-00-1, L-Histidine, reactions 72-18-4, L-Valine, reactions 73-22-3, L-Tryptophan, reactions 73-32-5, L-Isoleucine, reactions 74-79-3, L-Arginine, reactions 99-66-1, Valproic acid 103-90-2, Acetaminophen 107-35-7, Taurine 107-97-1, Sarcosine 147-85-3, L-Proline, reactions 305-84-0, Carnosine 327-57-1, L-Norleucine 498-59-9, Djenkolic acid 541-88-8 543-38-4, Canavanine 672-15-1, L-Homoserine 2078-54-8, Propofol 4530-20-5 5538-51-2, Acetylsalicyloyl chloride 5680-80-8 7738-22-9 13500-53-3 15098-69-8 15761-39-4 16597-50-5  
**17230-88-5**, Danazol 21209-51-8 30588-71-7 59865-13-3, Cyclosporin A 74103-07-4 120202-66-6 170850-75-6  
 (preparation of amino acid derivs. with high therapeutic index)

L17 ANSWER 2 OF 9 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN  
 DUPLICATE 1  
 AN 2006:153331 BIOSIS  
 DN PREV200600151873  
 TI Mastalgia - A review of management.  
 AU Olawaiye, Alexander; Withiam-Leitch, Matthew; Danakas, George; Kahn, Kenneth [Reprint Author]  
 CS SUNY Coll Buffalo, Dept Obstet Gynecol, Womens and Childrens Hosp, 219 Bryant St, Buffalo, NY 14222 USA  
 kenrkahn@buffalo.edu  
 SO Journal of Reproductive Medicine, (DEC 2005) Vol. 50, No. 12, pp. 933-939.  
 CODEN: JRPMPA. ISSN: 0024-7758.  
 DT Article  
 LA English  
 ED Entered STN: 1 Mar 2006  
 Last Updated on STN: 1 Mar 2006  
 AB. . . to two-thirds of women at some time during their reproductive lives. It is usually benign, but the fear of underlying **breast** cancer is why many women present for evaluation. Mastalgia can be associated with premenstrual syndrome, fibrocystic **breast** disease, psychologic disturbance and, rarely, **breast** cancer. Occasionally, extramammary conditions, like Tietzie syndrome, present as mastalgia. A thorough clinical evaluation is required to assess the cause. The majority of women can be reassured after a clinical evaluation. Approximately 1.5% require pain-relieving therapy. Mechanical **breast** support; a low-fat, high-carbohydrate diet; and **topical** nonsteroidal anti-inflammatory agents are reasonable first-line treatments. Hormonal agents, such as bromocriptine, tamoxifen and danazol, have all demonstrated efficacy in. . .  
 RN **17230-88-5** (danazol)

L17 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2  
 AN 2004:589389 CAPLUS  
 DN 141:128856  
 TI Pharmaceutical formulations for treatment of breast diseases  
 IN DiPiano, Gerianne Tringali; Mays, Peter Kevin  
 PA Femmepharm, Inc., USA  
 SO PCT Int. Appl., 18 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004060322	A2	20040722	WO 2004-US23	20040102
	WO 2004060322	A3	20050407		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ			

AU 2004203700	A1	20040722	AU 2004-203700	20040102
CA 2511995	A1	20040722	CA 2004-2511995	20040102
US 2004229813	A1	20041118	US 2004-751056	20040102
EP 1578421	A2	20050928	EP 2004-700078	20040102

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006515026	T	20060518	JP 2005-518791	20040102
PRAI US 2003-437778P	P	20030102		
WO 2004-US23	W	20040102		

AB Formulations for **topical** or local administration of drugs directly to the **breast** or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the **breast**, areola, or directly to the nipple. The formulations provide increased patient comfort, increased bioavailability and relatively high blood levels in the region to be treated with a reduction of side effects compared to those administered systemically. The preferred formulations contain drugs in the form of micro- or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion of foam. Skin permeability of danazol was clearly enhanced in the presence of 5% oleyl alc. The permeability of danazol was approx. 13-fold greater by using the carrier that contained 5% oleyl alc. in propylene glycol, relative to the carrier that contained 100% propylene glycol.

IT Drug delivery systems

(**topical**; pharmaceutical formulations for treatment of **breast** diseases)

IT 17230-88-5, Danazol

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulations for treatment of breast diseases)

L17 ANSWER 4 OF 9 USPATFULL on STN

AN 2004:292724 USPATFULL

TI Pharmaceutical preparations for treatments of diseases and disorders of the breast

IN DiPiano, Gerianne Tringali, Malvern, PA, UNITED STATES

Mays, Peter Kevin, Philadelphia, PA, UNITED STATES

PA Femme Pharma, Inc. (U.S. corporation)

PI US 2004229813 A1 20041118

AI US 2004-751056 A1 20040102 (10)

PRAI US 2003-437778P 20030102 (60)

DT Utility

FS APPLICATION

LREP PATREA L. PABST, PABST PATENT GROUP LLP, 400 COLONY SQUARE, SUITE 1200, ATLANTA, GA, 30361

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 518

CAS INDEXING IS AVAILABLE FOR THIS PATENT..

AB Formulations for **topical** or local administration of drugs directly to the **breast** or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the **breast**, areola, or directly to the nipple. The formulations provide increased patient comfort, increased bioavailability and relatively high blood levels in. . .

SUMM [0018] Non-steroidal anti-inflammatory drugs (NSAIDs) are sometimes prescribed for the treatment of **breast** pain. A prospective

study of the effectiveness of the **topical** application of NSAIDs as a gel formulation was carried out in 26 women with severe **breast** pain. A **topical** NSAID gel was applied as required and provided rapid relief of pain with no side effects in 81% of the. . .

SUMM [0020] Miltefosine (also known as MILTEX® and hexadecylphosphocholine) has been used **topically** to treat cutaneous manifestations of metastatic **breast** cancer. See e.g. C. Unger et al., Cancer Treat Rev 17: 243-246 (1990); J. Terwogt et al., Br J Cancer, . . . et al., J Clin Oncol, 19: 4150-4159 (2001). These reports indicate that the cytostatic drug, miltefosine, is useful to treat **topical** lesions arising from a primary neoplasia event in the **breast**. However, the drug does not treat neoplastic lesions within the **breast** tissue and the cutaneous metastatic tissue need not be localized to **breast** skin. Therefore, the drug is merely acting **topically** at the site of administration. Further, the drug is not effective at treating the underlying disease of the **breast**.

SUMM [0023] It is a further object of the present invention increase the bioavailability of drug administered **topically** to the **breast** or chest as compared to drugs administered systemically.

SUMM [0024] Formulations for **topical** or local administration of drugs other than non-steroidal antiinflammatories or analgesics such as lidocaine, such as hormones (and hormone releasing compounds) and analogs thereof, and chemotherapeutic agents, directly to the **breast** or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the **breast**, areola, or directly to the nipple. The formulations provide increased patient comfort, increased bioavailability and relatively high blood levels in.

DETD [0035] The drug is delivered to the **breast** tissue via local, **topical** or percutaneous delivery with suitable excipients or carriers to enable and/or enhance drug penetration. Suitable carriers or excipients may enhance. . .

DETD [0043] The formulations are preferably administered **topically** to the surface of the **breast** or chest, transported transdermally and delivered to **breast** tissue. The compositions are administered to treat diseases and disorders of the **breast**, chest and the underlying musculature. In particular, the compositions may be administered to treat benign diseases of the **breast**, including mastalgia, mastodynia, Mondor's disease, fibrocystic **breast** disease, costochondritis, mastitis, Paget's disease of the areola, fibroadenoma, **breast** abscess, and **breast** infections. Typically these will be administered at least once a day or as needed.

CLM What is claimed is:

. . . 1. A drug formulation comprising a drug in an amount effective to provide relief from diseases or disorders of the **breast** in a pharmaceutically acceptable carrier for **topical** administration to the **breast**, wherein the drug is not a non-steroidal antiinflammatory or analgesic.

10. A method for treating a disease or disorder of the of the **breast**, chest or underlying musculature comprising **topically** administering to the patient a drug formulation suitable for local or regional delivery comprising an effective amount of drug to. . .

IT 17230-88-5, Danazol

(pharmaceutical formulations for treatment of breast diseases)

reserved on STN

DUPLICATE 3

AN 2004232971 EMBASE  
TI Evidence for the management of mastalgia.  
AU Gumm R.; Cunnick G.H.; Mokbel K.  
CS Prof. K. Mokbel, Brunel Inst. Cancer Genet./P., Consultant Breast and  
Endocr. Surg., St. George's Hospital, Blackshaw Road, London SW17 0QT,  
United Kingdom. kefahmokbel@hotmail.com  
SO Current Medical Research and Opinion, (2004) Vol. 20, No. 5, pp. 681-684.

Refs: 30

ISSN: 0300-7995 CODEN: CMROCX

CY United Kingdom  
DT Journal; (Short Survey)  
FS 006 Internal Medicine  
010 Obstetrics and Gynecology  
030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles

LA English

SL English

ED Entered STN: 9 Jul 2004

Last Updated on STN: 9 Jul 2004

AB Mastalgia is the commonest **breast** symptom presenting to general  
practitioners and **breast** surgeons alike. To make a full  
assessment of the cause, all patients require a full history, examination  
and, sometimes, investigations.. . . and bromocriptine, but these have  
a higher side-effect profile and are rarely indicated nowadays. Newer  
treatments include lisuride maleate and **topical** non-steroidal  
anti-inflammatory preparations.

RN (caffeine) 30388-07-9, 58-08-2; (tamoxifen) 10540-29-1; (danazol)  
**17230-88-5**; (bromocriptine) 25614-03-3; (lisuride maleate)  
19875-60-6

L17 ANSWER 6 OF 9 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights  
reserved on STN

AN 2001019211 EMBASE

TI Sports brassiere: Is it a solution for mastalgia?.

AU Abdel Hadi M.S.A.

CS Dr. M.S.A. Abdel Hadi, Department of Surgery, King Fahd Hospital of the  
University, P.O. Box 2208, Alkhobar 31952, Saudi Arabia.  
abdelhadi\_m@hotmail.com

SO Breast Journal, (2000) Vol. 6, No. 6, pp. 407-409. .

Refs: 11

ISSN: 1075-122X CODEN: BRJOFK

CY United States

DT Journal; Article

FS 003 Endocrinology  
009 Surgery  
017 Public Health, Social Medicine and Epidemiology  
037 Drug Literature Index  
038 Adverse Reactions Titles

LA English

SL English

ED Entered STN: 25 Jan 2001

Last Updated on STN: 25 Jan 2001

AB **Breast** pain is a very common complaint in women presenting to  
the outpatient department. It causes a certain degree of discomfort,. .  
. . a chronic course. Many patients are unsatisfied with prescribed  
medications and tend to discontinue treatment when side effects develop.  
Active **breast** movement on its weak suspensory ligaments may  
contribute considerably to mastalgia. Good **external** support by  
sports brassieres can relieve most of the patient's symptoms.

RN (danazol) **17230-88-5**


L17 ANSWER 7 OF 9 DRUGU COPYRIGHT 2007 THE THOMSON CORP on STN  
 AN 1992-11452 DRUGU T S E  
 TI Elimination of Ovulation and Menstrual Cyclicity (with Danazol) Improves  
 Dysphoric Premenstrual Syndromes.  
 AU Halbreich U; Rojansky N; Palter S  
 LO Buffalo, New York, United States  
 SO Fertil.Steril. (56, No. 6, 1066-69, 1991) 1 Fig. 25 Ref.  
 CODEN: FESTAS ISSN: 0015-0282  
 AV Department of Psychiatry, State University of New York at Buffalo, 462  
 Grider Street, K-Annex, Buffalo, New York 14215, U.S.A.  
 LA English  
 DT Journal  
 FA AB; LA; CT  
 FS Literature  
 AB. . . did not respond to initial placebo therapy. DA was withdrawn  
 because of skin rash, increased headache, nausea and vomiting, decreased  
**breast** size, **external** stress and improvement of  
 symptoms. DA also caused hot flushes, weight gain, bloatedness, acne,  
 vaginal infection and craving for sweets.. . .  
 ABEX. . . 1 with skin rash and increased headache, respectively. 4 Patients  
 withdrew in mth 2 with nausea and vomiting (2), decreased **breast**  
 size (1), **external** stress and improvement of symptoms (1). DA  
 also caused hot flushes in 3 patients, weight gain and bloatedness in 9,.  
 . .  
 RN [01] 17230-88-5  
 . . .  
 L17 ANSWER 8 OF 9 BIOTECHNO COPYRIGHT 2007 Elsevier Science B.V. on STN  
 AN 1986:16120681 BIOTECHNO  
 TI Endocrine-responsive pancreatic carcinoma: Steroid binding and  
 cytotoxicity studies in human tumor cell lines  
 AU Benz C.; Hollander C.; Miller B.  
 CS Cancer Research Institute, University of California, San Francisco, CA  
 94143, United States.  
 SO Cancer Research, (1986), 46/5 (2276-2281)  
 CODEN: CNREA8  
 DT Journal; Article  
 CY United States  
 LA English  
 AB. . . pancreatic cancer by comparing human (MiaPaCa, Colo-357, RWP-1,  
 RWP-2) and rodent (AR42j) pancreatic tumor cell lines with cultured  
 estrogen receptor-positive **breast** cancer cells (MCF-7, T47-D).  
 The four human pancreatic tumors contain measurable levels of specific  
 estradiol binding sites with dissociation constants (K(d)) that range  
 from 1 to 9 nM, in contrast to the higher-affinity binding sites measured  
 in the **breast** cancer cells (K(d) <= 1 nM). Growth of one  
 pancreatic tumor line (MiaPaCa) is stimulated 40% above control by  
 exposure. . . .  
 CT. . . \*pancreas carcinoma; radioisotope; cell culture; human; rat; tumor  
 cell line; pancreas; priority journal; endocrine system; in vitro study;  
 pharmacokinetics; intoxication; **topical** drug administration;  
 human cell; animal cell; **breast**  
 RN (17beta (n,n diethylcarbamoyl) 4 methyl 4 aza 5alpha androstan 3 one)  
 73671-86-0; (danazol) 17230-88-5; (dexamethasone) 50-02-2;  
 (estradiol) 50-28-2; (fluoxymesterone) 76-43-7; (hydrocortisone) 50-23-7;  
 (medroxyprogesterone acetate) 71-58-9; (progesterone) 57-83-0;  
 (promegestone) 34184-77-5; (tamoxifen) 10540-29-1  
 CN Drug Trade. . . .  
 . . .  
 L17 ANSWER 9 OF 9 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights  
 reserved on STN  
 AN 82104496 EMBASE  
 DN 1982104496

TI Female pseudohermaphroditism with somatic chromosomal anomaly in  
association with in utero exposure to danazol.  
AU Peress M.R.; Kreutner A.K.; Mathur R.S.; Williamson H.O.  
CS Sect. Reprod. Endocrinol. Infertil., Dept. Obstet. Gynecol., Med. Univ.  
South Carolina, Charleston, SC 29425, United States  
SO American Journal of Obstetrics and Gynecology, (1982) Vol. 142, No. 6 I,  
pp. 708-709. .  
CODEN: AJOGAH  
CY United States  
DT Journal  
FS 038 Adverse Reactions Titles  
037 Drug Literature Index  
010 Obstetrics and Gynecology  
022 Human Genetics  
003 Endocrinology  
021 Developmental Biology and Teratology  
005 General Pathology and Pathological Anatomy  
LA English  
ED Entered STN: 9 Dec 1991  
Last Updated on STN: 9 Dec 1991  
AB Female pseudohermaphroditism is characterized by XX karyotype, female  
internal reproductive organs, but ambiguous **external** genitals,  
usually as a result of in utero exposure to excess androgens. Such  
androgens may be of exogenous, fetal, or. . . of female  
pseudohermaphroditism with in utero exposure to danazol. This compound  
has been used in the treatment of endometriosis, fibrocystic  
**breast** disease, precocious puberty, dysfunctional uterine  
bleeding, and angioneurotic edema.  
RN (danazol) 17230-88-5

=>

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 17230-88-5 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 $\alpha$ )- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 17 $\alpha$ -Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol (8CI)  
 CN 1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol, 1-ethynyl-  
 2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl- (7CI)  
 CN 1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazole, prena-2,4-dien-20-yno[2,3-  
 d]isoxazol-17-ol deriv.  
 OTHER NAMES:  
 CN 17 $\alpha$ -Pregna-2,4-dien-20-yne-[2,3-d]isoxazole-17 $\beta$ -ol  
 CN Bonzol  
 CN Chronogyn  
 CN Cyclomen  
 CN **Danazol**  
 CN Danazolium  
 CN Danocrine  
 CN Danol  
 CN Danovaol  
 CN Danzol  
 CN Ladogal  
 CN NSC 270916  
 CN Win 17757  
 CN Winobanin  
 FS STEREOSEARCH  
 MF C22 H27 N O2  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO,  
 CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM,  
 DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE,  
 MRCK\*, MSDS-OHS, PHAR, PROMT, PS, RTECS\*, SPECINFO, TOXCENTER, USAN,  
 USPAT2, USPATFULL, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


779 REFERENCES IN FILE CA (1907 TO DATE)  
 15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 781 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=>



L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 10540-29-1 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-  
 CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI)  
 CN Ethylamine, 2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-  
 (8CI)  
 OTHER NAMES:  
 CN (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine  
 CN ICI 47699  
 CN Mammaton  
 CN **Tamoxifen**  
 CN trans-Tamoxifen  
 CN Z-Tamoxifen  
 FS STEREOSEARCH  
 MF C26 H29 N O  
 CI COM  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*,  
 BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX,  
 CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB\*, IMSCOSEARCH,  
 IMSPATENTS, IPA, MEDLINE, MRCK\*, MSDS-OHS, PHAR, PROMT, PS, RTECS\*,  
 SCISEARCH, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7479 REFERENCES IN FILE CA (1907 TO DATE)  
 175 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 7509 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>



1-(p-dimethylaminoethoxyphenyl)trans-1-(p-hydroxyphenyl)-2-phenylbut-1-ene